文献速递神经肿瘤功能神经外科

垂体腺瘤现代放疗技术的长期结局:单中心经验

Long-term outcomes of modern radiation therapy for pituitary adenoma - different techniques: single institute experience.
PubMed 文献 · J Neurooncol · 2025-09-10

该单中心回顾性研究分析了1992至2023年间122例接受现代放疗的垂体腺瘤患者,中位随访107个月,5年和20年局部控制率分别为95%和75%,质子治疗较光子治疗显著改善局部控制和总生存(p < 0.01),垂体功能减退是最常见远期毒性(40%)。

要点

  • 现代放疗为垂体腺瘤提供持久局部控制,5年95%、20年75%。
  • 质子治疗较光子治疗显著改善局部控制和总生存(p < 0.01)。
  • 垂体功能减退最常见远期毒性(40%),视觉损害罕见(< 3%)。

核心结论

  • 现代放疗技术尤其质子治疗为垂体腺瘤提供持久肿瘤控制和可管理的毒性。
  • 优化放疗时机和精准度对改善结局和减少并发症至关重要。
  • 长期随访对监测疾病进展和晚期毒性仍必不可少。

研究设计与样本

  • 单中心回顾性分析德国三级医院1992至2023年间122例接受放疗的垂体腺瘤患者。
  • 采用Kaplan-Meier分析评估总生存和局部控制,log-rank检验比较亚组。
  • 毒性按CTCAE 5.0版分级。

主要发现

  • 中位随访自初诊107个月、放疗后63个月。
  • 96%患者接受分次立体定向放疗,4%接受单次放射外科。
  • 放疗后5年和20年局部控制率分别为95%和75%。
  • 质子治疗较光子治疗显著改善局部控制和总生存(p < 0.01)。
  • 垂体功能减退发生率40%,视觉损害< 3%,肿瘤复发9%。

关键数值与推荐

  • 局部控制率:5年95%、20年75%。
  • 质子治疗较光子治疗改善局部控制和总生存,p < 0.01。
  • 垂体功能减退发生率40%,视觉损害< 3%,复发率9%。

临床怎么用

  • 对术后残留、复发或激素高分泌的垂体腺瘤患者可考虑现代放疗。
  • 质子治疗可能优先用于需改善局部控制和生存的患者。
  • 放疗后需长期监测垂体功能和视觉并发症。

局限性

  • 单中心回顾性设计。
  • 样本量122例。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pituitary adenomas are relatively common benign intracranial tumors that may cause significant hormonal imbalances and visual impairments. Radiotherapy (RT) remains an important treatment option, particularly for patients with residual tumor after surgery, recurrent disease, or ongoing hormonal hypersecretion. This study summarizes long-term clinical outcomes and radiation-associated toxicities in patients with pituitary adenomas treated with contemporary radiotherapy techniques at a single institution. METHODS: A retrospective analysis was conducted on 122 patients treated with RT for pituitary adenomas at the tertiary Hospital in Germany between 1992 and 2023. Patient data were assessed for tumor characteristics, treatment modalities, and outcomes. Overall survival (OS), and local control (LC) were evaluated using Kaplan-Meier analysis. Statistical comparisons between subgroups were performed with the log-rank test. Treatment-related toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. RESULTS: Median follow-up was 107 months from initial diagnosis and 63 months post-RT. Most patients (96%) received fractionated stereotactic radiotherapy (FSRT), and 4% underwent single-session radiosurgery. RT achieved LC rates of 95% and 75% at 5 and 20 years, respectively. Proton therapy significantly improved LC and overall survival (OS) compared to photon-based treatments (p < 0.01). Hypopituitarism was the most common long-term toxicity, occurring in 40% of patients, while visual impairments were rare (< 3%). Tumor recurrence occurred in 9% of patients, primarily in those treated with delayed RT after incomplete resection. CONCLUSION: Modern RT techniques, particularly proton therapy, provide durable tumor control and manageable toxicity profiles for pituitary adenomas. Optimized timing and precision in RT delivery are critical to enhancing outcomes and minimizing complications. Long-term follow-up remains essential to monitor disease progression and late toxicities.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Brand A, Agolli L, Tas KT, et al. Long-term outcomes of modern radiation therapy for pituitary adenoma - different techniques: single institute experience. J Neurooncol. 2025. PMID: 40928610. doi:10.1007/s11060-025-05228-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。